Today, Halt Medical® and DFI® are pleased to announce our joint and cooperative efforts for new products to the medical industry. Halt Medical® is a leading medical device innovator focused on establishing a new standard of care for women with symptomatic uterine fibroids and DFI® is a global supplier focused on manufacturing leading-edge board and system level products for embedded applications that require strict revision control and long life availability. With a view to increase the medical device reliability, sustainability, and accuracy, Halt Medical® has chosen DFI-ITOX as supplier in their Acessa™ System for minimally invasive treatment.
In 2004, Halt Medical®, Inc. was founded to develop and manufacture the medical device. Halt-Medical developed the Acessa™ System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa™ System has been successfully used to treat more and more patients and the quality of their life has sharply improved.
DFI-ITOX, located in Piscataway, NJ, is a fully owned subsidiary of DFI® Inc. located in Taipei, Taiwan. In business since 1981, DFI® is a leading supplier of motherboards, modules and systems in the embedded industry. With more than 33 years of experience, DFI® uses the latest technology platforms and manufacturing techniques to produce cost-effective products as well as provide well-rounded support and services. The partnership with Halt Medical® signified that DFI® is now firmly established in business as a reliable manufacturer in the medical field. In addition to the medical industry, DFI® is also active in such areas of application such as industrial automation, transportation, gaming, POS, power generation and digital signage. DFI® offers shorter development time and lower development cost of embedded products for use in a wide range of industrial applications.
The medical solution provided by DFI® for the Halt Medical® Acessa™ System is DS912-OT. This compact design system is powered by the graphics-rich AMD® embedded G-series APU and its dual display outputs with smooth video playback are available for multi-monitor. DS912-OT provides 2 DDR3 SODIMM sockets supporting up to 16GB and is equipped with 1 2.5” SATA drive bay as well as 1 SD/MMC slot. For additional storage, 1 mSATA module can be installed in this system via a Mini PCIe slot and therefore makes it ideal for this space-limited Acessa™ System.
The Acessa™ Procedure, also known as radiofrequency volumetric thermal ablation (RFVTA), is a new minimally-invasive laparoscopic treatment for symptomatic fibroids of all types and sizes. By using its intraoperative ultrasound, the surgeon is able to clearly identify all of the patient’s fibroids and destroy them; therefore, the DS912-OT is the right solution that provides high computing capability for delivering accurate data and fast processing performance for high-resolution and real-time imaging. The combination of the Acessa™ System and DFI’s reliable platform has shown high patient satisfaction levels and very low need for further fibroid treatment.
Halt Medical® has many years of experience in developing the Acessa™ System for fibroids treatment and the Acessa™ Procedure represents a major breakthrough in addressing one of the biggest unmet needs in women’s health. DFI® is a global provider offering a wide range of products for diversified industrial applications. Halt Medical’s Acessa™ System, using DFI’s latest technology, enables Halt Medical® to be on the forefront of the medical industry.
For more information on Halt Medical® (Acessa™), contact:
For more information on DFI®, contact:
For more information on DFI-ITOX, contact:
Scott Campion, DFI-ITOX Regional Sales Manager